AIDS-related Non-Hodgkin's Lymphoma: Etiology, Epidemiology, and Impact of Highly Active Antiretroviral Therapy

References

• Gaspar, B., Sharifi, R., Kinnon, C. et al. (2001) Sap gene transfer restores cytotoxic function in EBV-CTLS generated from individuals with XLP. Paper presented at American Society of Hematology, San Francisco, 2001.
   Google Scholar
• Rezza, G. (2000) "Immunosuppression, timing of human herpes-virus 8 infection, and risk of Kaposi's sarcoma among human immunodeficiency virus type 1-infected persons and transplant recipients", Journal of Infectious Diseases, 182, 1809–1810.
   PubMed Web of Science ®Google Scholar
• Nagy, S., Gyulai, R., Kemeny, L., Szenohradszky, P. and Dobozy, A. (2000) "Iatrogenic Kaposi's sarcoma: HHV8 positivity persists but the tumors regress almost completely without immunosuppres-sive therapy", Transplantation, 69, 2230— 2231.
   Google Scholar
• Gruhn, B., Meerbach, A., Hafer, R., etal. (2001) Early diagnosis and pre-emptive therapy of Epstein-Barr virus-associated lymphoproli-ferative disease following hematopoietic stem cell transplantation. Paper presented at American Society of Hematology, Orlando, 2001.
   Google Scholar
• Savoldo, B., Gross, J., Karpen, S., et al. (2002) Humanized anti-CD20 monoclonal antibody for the treatment of lymphoproliferative disease developing in pediatric solid organ transplant recipients. Paper presented at Sixth International Conference on Malignancies in AIDS & Other Immunodeficiencies: Basic, Epidemiologic & Clinical Research, Bethesda, April 22–24, 2002.
   Google Scholar
• Liu, Z., Savoldo, B., Huls, H., Lopez, T., Gee, A., Wilson, J., et al. (2002) "Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas", Recent Results in Cancer Research, 159, 123–133.
   Google Scholar
• Kamel, 0.W., van de Rijn, M., Weiss, L.M., Del Zoppo, G.J., Hench, P.K., Robbins, B.A., et al. (1993) "Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis", New England Journal of Medicine, 328, 1317 — 1321.
   PubMed Web of Science ®Google Scholar
• Speight, P.M., Jordan, R., Colloby, P., Nandha, H. and Pringle, J.H. (1994) "Early detection of lymphomas in Sjogren's syndrome by in situ hybridisation for kappa and lambda light chain mRNA in labial salivary glands", European Journal of Cancer. Part B, Oral Oncology, 30B, 244–247.
   PubMed Web of Science ®Google Scholar
• Levine, A.M., Shibata, D., Sullivan-Halley, J., Nathwani, B., Brynes, R., Slovak, ML., et al. (1992) "Epidemiological and biological study of acquired immunodeficiency syndrome-related lymphoma in the County of Los Angeles: preliminary results", Cancer Research, 52 (19 Suppl.), 5482s— 5484s.
   Google Scholar
• Knowles, D.M. (1996) "Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma", Hematology/Oncology Clinics of North America, 10, 1081 — 1109.
   PubMed Web of Science ®Google Scholar
• Levine, A.M. (1992) "AIDS-associated malignant lymphoma", Medical Clinics of North America, 76, 253–268.
   PubMed Web of Science ®Google Scholar
• Gaidano, G., Pastore, C., Lanza, C., Mazza, U. and Saglio, G. (1994) "Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity", Annals of Hematol-ogy, 69, 281 — 290.
   PubMed Web of Science ®Google Scholar
• Carbone, A., Gloghini, A., Larocca, L.M., Capello, D., Pierconti, F., Canzonieri, V., et al. (2001) "Expression profile of MUM1/ IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas", Blood, 97, 744–751.
   PubMed Web of Science ®Google Scholar
• Ballerini, P., Gaidano, G., Gong, J., Tassi, V., Saglio, G., Knowles, D.M., et al. (1992) "Molecular pathogenesis of HIV-associated lymphomas", AIDS Research and Human Retroviruses, 8, 731 —735.
   PubMed Web of Science ®Google Scholar
• Ballerini, P., Gaidano, G., Gong, J.Z., Tassi, V., Saglio, G., Knowles, D.M., et al. (1993) "Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma", Blood, 81, 166 — 176.
   Google Scholar
• Carbone, A., Gaidano, G., Gloghini, A., Larocca, L.M., Capello, D., Canzonieri, V., et al. (1998) "Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent mem-brane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas", Blood, 91, 747–755.
   PubMed Web of Science ®Google Scholar
• Delecluse, H.J., Raphael, M., Magaud, J.P., Felman, P., Alsamad, IA., Bornkamm, G.W., et al. (1993) "Variable morphology of human immunodeficiency virus-associated lymphomas with c-myc rearrangements", The French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors, I. Blood, 82, 552 — 563.
   PubMed Web of Science ®Google Scholar
• Schlaifer, D., Brousset, P., Attal, M., Massip, P., Payen, C., Marchou, B., et al. (1994) "bc1-2 proto-oncogene and Epstein-Barr virus latent membrane protein-1 expression in AIDS-related lymphoma", Histopathology, 25, 77–82.
   PubMed Web of Science ®Google Scholar
• Gaidano, G., Pastore, C. and Volpe, G. (1995) "Molecular pathogenesis of non-Hodgkin lymphoma: a clinical perspective", Haematologica, 80, 454–472.
   PubMed Web of Science ®Google Scholar
• Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, RI., et al. Lymphoma/Leukemia Molecular Profiling Project. (2002) "The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma", New England Journal of Medicine, 346, 1937— 1947.
   Web of Science ®Google Scholar
• Alizadeh, A.A., Eisen, MB., Davis, RE., Ma, C., Lossos, IS., Rosenwald, A., et al. (2000) "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling", Nature, 403, 503— 511.
   Google Scholar
• Gascoyne, RD., Adomat, S.A., Krajewski, S., Krajewska, M., Horsman, D.E., Tolcher, A.W., et al. (1997) "Prognostic signifi-cance of Bc1-2 protein expression and Bc1-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma", Blood, 90, 244–251.
   PubMed Web of Science ®Google Scholar
• Kramer, M.H., Hermans, J., Wijburg, E., Philipp), K., Geelen, E., van Krieken, J.H., et al. (1998) "Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma", Blood, 92, 3152–3162.
   PubMed Web of Science ®Google Scholar
• King, J.T. Jr, Justice, AC., Roberts, M.S., Chang, CC. and Fusco, J.S. Collaboration in HIV Outcomes Research-US Program Team(2003) "Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era", Medical Decision Making, 23, 9–20.
   PubMed Web of Science ®Google Scholar
• Besson, C., Goubar, A., Gabarre, J., Rozenbaum, W., Pialoux, G., Chatelet, F.P., et al. (2001) "Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy", Blood, 98, 2339–2344.
   Google Scholar
• Kalter, S.P., Riggs, S.A., Cabanillas, F., Butler, J.J., Hagemeister, F.B., Mansell, P.W., et al. (1985) "Aggressive non-Hodgkin's lymphomas in immunocompromised homosexual males", Blood, 66, 655–659.
   Google Scholar
• Ziegler, J.L., Drew, W.L., Miner, R.C., Mintz, L., Rosenbaum, E., Gershow, J., et al. (1982) "Outbreak of Burkitt's-like lymphoma in homosexual men", Lancet, 2, 631–633.
   Google Scholar
• Pluda, J.M., Venzon, Di., Tosato, G., Lietzau, J., Wyvill, K., Nelson, DL., et al. (1993) "Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immuno-deficiency virus infection receiving antiretroviral therapy", Journal of Clinical Oncology, 11, 1099 — 1107.
   Google Scholar
• Dana, B.W., Dahlberg, S., Miller, T.P., Hartsock, R.J., Balcerzak, S., Coltman, CA., et al. (1990) "m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial", Journal of Clinical Oncology, 8, 1155— 1162.
   PubMed Web of Science ®Google Scholar
• Walsh, C., Wernz, J.C., Levine, A., Rarick, M., Willson, E., Melendez, D., et al. (1993) "Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-asso-ciated non-Hodgkin's lymphoma", Journal of Acquired Immune Deficiency Syndromes, 6, 265–271.
   Google Scholar
• Levine, AM., Wernz, J.C., Kaplan, L., Rodman, N., Cohen, P., Metroka, C., et al. (1991) "Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial", Journal of the American Medical Association, 266, 84— 88.
   PubMed Web of Science ®Google Scholar
• Kaplan, L.D., Straus, DJ., Testa, MA., Von Roenn, J., Dezube, B.J. and Cooley, T.P. (1997) "Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. Na-tional Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group", New England Journal of Medicine, 336, 1641 — 1648.
   Web of Science ®Google Scholar
• Fisher, RI., Gaynor, ER., Dahlberg, S., Oken, MM., Grogan, TM., Mize, EM., et al. (1993) "Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma", New England Journal of Medicine, 328, 1002–1006.
   Google Scholar
• Wilson, W.H. (1997) Chemotherapy for AIDS-related lymphomas [letter; comment]. New England Journal of Medicine, 337, 1172 — 1173; discussion 1173–1174.
   Google Scholar
• Ratner, L., Redden, D., Hamzeh, F., et al. (1999) Chemotherapy for HIV-NHL in combination with HAART. Paper presented at 3rd National AIDS Malignancy Meeting; Bethesda, May 26–28, 1999.
   Google Scholar
• Antinori, A., Cingolani, A., Alba, L., Ammassari, A., Serraino, D., Ciancio, B.C., et al. (2001) "Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy", Aids, 15, 1483–1491.
   Google Scholar
• Levine, AM., Sullivan-Halley, J., Pike, MC., Rarick, MU., Loureiro, C., et al. (1991) "Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival", Cancer, 68, 2466— 2472.
   PubMed Web of Science ®Google Scholar
• Straus, Di., Huang, J., Testa, M.A., Levine, A.M. and Kaplan, L.D. (1998) "Prognostic factors in the treatment of human immunodeficiency virus- associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142 - low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases", Journal of Clinical Oncology, 16, 3601 — 3606.
   Google Scholar
• Vaccher, E., Spina, M., di Gennaro, G., Talamini, R., Nasti, G., Schioppa, 0., et al. (2001) "Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodefi-ciency virus-related, non-Hodgkin lymphoma", Cancer, 91, 155 — 163.
   PubMed Web of Science ®Google Scholar
• Ratner, L., Lee, J., Tang, S., Redden, D., Hamzeh, F., Herndier, B., et al. AIDS Malignancy Consortium. (2001) "Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lympho-ma in combination with highly active antiretroviral therapy", Journal of Clinical Oncology, 19, 2171 —2178.
   PubMed Web of Science ®Google Scholar
• Spina, M., Vaccher, E., Juzbasic, S., Milan, I., Nasti, G., Talamini, R., et al. (2001) "Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients", Cancer, 92, 200–206.
   Google Scholar
• Tirelli, U., Spina, M., Jaeger, U., Nigra, E., Blanc, P.L., Liberati, AM., et al. (2002) "Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodg-kin's lymphoma: preliminary results of a phase I/II study", Recent Results in Cancer Research, 159, 149 — 153.
   PubMedGoogle Scholar
• Mackall, CL., Fleisher, TA., Brown, MR., Magrath, IT., Shad, AT., Horowitz, ME., et al. (1994) "Lymphocyte depletion during treatment with intensive chemotherapy for cancer", Blood, 84, 2221–2228.
   Google Scholar
• Phenix, B.N., Lum, ii., Nie, Z., Sanchez-Dardon, J. and Badley, AD. (2001) "Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss", Blood, 98, 1078 — 1085.
   PubMed Web of Science ®Google Scholar
• Mellors, J.W., Rinaldo, C.R. Jr, Gupta, P., White, R.M., Todd, J.A. and Kingsley, L.A. (1996) "Prognosis in HIV-1 infection predicted by the quantity of virus in plasma", Science, 272, 1167–1170.
   PubMed Web of Science ®Google Scholar
• Vaccher, E., Spina, M., Santarossa, S., et al. (1998) Concomitant CHOP chemotherapy (CT) and highly active antiretroviral therapy (HAART) in patients with HIV-related non-Hodgkin's lymphoma (HIV-NHL). Paper presented at International Conference on AIDS, Geneva, 1998.
   Google Scholar
• Little, R.F., Pittaluga, S., Grant, N., Steinberg, S.M., Kavlick, M.F., Mitsuya, H., et al. (2003) "Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology", Blood, 101, 4653–4659.
   Google Scholar
• Raphael, M., Lamine, M., Abd Alsamad, I., Debre, P. and Binet, J.L. (1992) "Non-Hodgkin's lymphoma and AIDS: histopathologic features", Archives d'anatomie et de Cytologie Pathologique, 40, 105 —109.
   PubMedGoogle Scholar
• Bauer, K.D., Merkel, D.E., Winter, J.N., Marder, R.J., Hauck, W.W., Wallemark, C.B., et al. (1986) "Prognostic implications of ploidy and proliferative activity in diffuse large cell lymphomas", Cancer Research, 46, 3173–3178.
   Google Scholar
• Miller, T.P., Grogan, TM., Dahlberg, S., Spier, C.M., Braziel, R.M., Banks, P.M., etal. (1994) "Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial", Blood, 83, 1460–1466.
   PubMed Web of Science ®Google Scholar
• Wilson, W.H., Teruya-Feldstein, J., Fest, T., Harris, C., Steinberg, S.M., Jaffe, ES., et al. (1997) "Relationship of p53, bc1-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas", Blood, 89, 601 —609.
   PubMed Web of Science ®Google Scholar
• Tulpule, A., Sherrod, A., Dharmapala, D., Young, L.L., Espina, B.M., Sanchez, M.N., et al. (2002) "Multidrug resistance (MDR-1) expression in aids-related lymphomas", Leukemia Research, 26, 121–127.
   PubMed Web of Science ®Google Scholar
• Lai, G.M., Chen, Y.N., Mickley, L.A., Fojo, AT. and Bates, S.E. (1991) "P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines", International Journal of Cancer, 49, 696–703.
   Google Scholar
• Kaplan, L. (2003) No benefit from rituximab in a randomized phase iii trial of CHOP with or without rituximab for patients with HIV-associated non-Hodgkin's lymphoma: AIDS Malignancies Consor-tium Study 101. Paper presented at The Seventh International Conference on Malignancies in AIDS and Other Immunodeficien-cies; Bethesda, April 28–29, 2003.
   Google Scholar
• Vose, J.M., Link, BK., Grossbard, ML., Czuczman, M., Grillo-Lopez, A., Gilman, P., et al. (2001) "Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma", Journal of Clinical Oncology, 19, 389–397.
   PubMed Web of Science ®Google Scholar
• Gutierrez, M., Grossbard, M., Little, R., et al. (2000) Dose-adjusted EPOCH chemotherapy (CT) and rituximab (EPOCH-R): an effective regimen in poor prognosis aggressive B-cell non-Hodgkin's lymphoma (NHL). Paper presented at 36th Annual Proceedings of the American Society of Clinical Oncology, New Orleans, 2000.
   Google Scholar
• Mackall, CL., Fleisher, TA., Brown, MR., Andrich, M.P., Chen, C.C., Feuerstein, TM., et al. (1995) "Age, thymopoiesis, and CD4 + T-lymphocyte regeneration after intensive chemotherapy", New England Journal of Medicine, 332, 143–149.
   PubMed Web of Science ®Google Scholar